Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Palatin (PLTN) -- Ignore unavailable to you. Want to Upgrade?

To: TradeOfTheDay who wrote (25)	5/12/1998 4:29:00 PM
From: cheech	Respond to of 61

As usual goes down with good news. Whats next? Anyone?

To: TradeOfTheDay who wrote (25)	6/16/1998 11:12:00 PM
From: incomep	Read Replies (1) \| Respond to of 61

Any idea how big the future market for LeuTech imaging? 7/23, the LeuTech will start the phase III clinical trial. How long will it take to finish phase III? Palatin Technologies Names Charles Putnam Chief Operating Officer Fills New Corporate Position PRINCETON, N.J.--(BW HealthWire)--June 15, 1998--Palatin Technologies Inc. (Nasdaq: PLTN - news) Monday announced the promotion of Charles L. Putnam, 45, to the newly-created position of chief operating officer. Putnam will continue as executive vice president for operations and product development, a post he has held since the company's inception two years ago. In his new position, Putnam is responsible for R&D, marketing, manufacturing, quality control and clinical and regulatory affairs. Putnam has been responsible for spearheading the company's lead product LeuTech(TM), a diagnostic for infection imaging. In addition, he was instrumental in the development of a research facility the company operates in Edison, N.J. Putnam will continue to report to Chairman, President and Chief Executive Officer Edward J. Quilty. An 18-year veteran of the medical device and hospital supply industry, Putnam was formerly executive vice president, research & development, for MedChem Products Inc., a Woburn, Mass.-based manufacturer and marketer of specialty medical products acquired in 1996 by C.R. Bard Inc. Quilty commented: ''Charlie Putnam's in-depth executive-level experience with research and operations will add substantially to the company's continuing growth. His overseeing day-to-day operations will allow Dr. Carl Spana, our chief technology officer, and me to concentrate our energies on corporate finance, product acquisition opportunities and joint development programs with corporate partners.'' In addition to holding several medical device patents, Putnam has a record of success at several corporate levels, from start-up companies to multinational entities. Other prior management positions included service as vice president of operations and research development at Princeton-based Life Medical Sciences; Director of Device Development at Danbury, Conn.-based Davis & Geck division of American Cyanamid Corp.; Machlett Laboratories division of Raytheon Corp., in Stamford, Conn.; Burndy Corp. Fairfield, Conn., and management posts in product development and manufacturing at Ford Motor company in Deerfield, Mich. He holds a degree in mechanical engineering from Worcester (MA) Polytechnic. Putnam lives with his family in Belle Mead, N.J. Palatin Technologies is a development-stage technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development based on its proprietary monoclonal antibody, radiolabeling and enabling peptide platform technologies.